Preservation of β-Cell Function: The Key to Diabetes Prevention
The DOI matches its Crossref record; 132 of the 132 references it cites were found in a registry or an index.
Abstract
CONTEXT: The Centers for Disease Control and Prevention estimates that there are approximately 79,000,000 individuals in the United States with prediabetes [impaired glucose tolerance (IGT) and/or impaired fasting glucose] and that approximately 40-50% will progress to type 2 diabetes mellitus (T2DM) during their lifetime. Therefore, treatment of high-risk IGT individuals to prevent T2DM has important medical, economic, social, and human implications. Individuals in the upper tertile of IGT are maximally/near-maximally insulin resistant, have lost 70-80% of their β-cell function, and have approximately a 10% incidence of diabetic retinopathy. Therefore, preservation of the remaining 20-30% of β-cell function is critical to prevent future development of T2DM. EVIDENCE ACQUISITION: We searched MEDLINE from 2000 to the present to identify placebo-controlled trials in which individuals with IGT received pharmacological therapy to prevent progression to diabetes. EVIDENCE SYNTHESIS: Lifestyle modification reduces IGT conversion to T2DM, but it is difficult to implement and maintain. Moreover, 40-50% of IGT subjects progress to T2DM despite weight loss. In contrast, pharmacological intervention with medications that reverse known pathophysiological abnormalities (β-cell dysfunction and insulin resistance) uniformly prevents IGT progression to T2DM. Thiazolidinediones reduce IGT conversion to diabetes by approximately 50-70%. Metformin in the U.S. Diabetes Prevention Program reduced the development of T2DM by 31% and has been recommended by the American Diabetes Association. Because glucagon-like peptide-1 analogs augment insulin secretion, preserve β-cell function, and promote weight loss, they may be efficacious in preventing IGT progression to T2DM. CONCLUSION: Pharmacological intervention with a variety of agents (thiazolidinediones, metformin, acarbose, glucagon-like peptide-1 analogs) consistently reduces the rate of conversion of IGT to T2DM.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Fasting plasma glucose values are determined by endogenous glucose production (EGP) that is mostly dependent on the liver.”
From Prediabetes: a high-risk state for diabetes development (2012) · cites this paper as [45]
In the citing paper
“The product of EGP and fasting insulin is used as a marker of hepatic insulin resistance and it shows a relatively strong relationship with fasting glycaemia.38,39,45”
From Prediabetes: a high-risk state for diabetes development (2012) · cites this paper as [45]
In the citing paper
“Both IFG and IGT subjects present with insulin resistance, however the site of insulin resistance is different: High hepatic insulin resistance is a typical finding in IFG with almost normal values in skeletal muscle.38,39,45 In IGT, the main site of insulin resistance is the muscle with only modest changes in liver insulin sensitivity.37,38”
From Prediabetes: a high-risk state for diabetes development (2012) · cites this paper as [45]
In the citing paper
“The primary aim of lifestyle interventions is to prevent or delay the development of type 2 diabetes and its complications13,45 by targeting obesity and physical inactivity, the two most important modifiable risk factors of diabetes development.3,25”
From Prediabetes: a high-risk state for diabetes development (2012) · cites this paper as [45]
In the citing paper
“The glitazones, such as troglitazone, rosiglitazone and pioglitazone, act through the PPAR-γ receptor by increasing hepatic and peripheral insulin sensitivity and preserving insulin secretion.45,95”
From Prediabetes: a high-risk state for diabetes development (2012) · cites this paper as [45]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Wild, S., Roglic, G., Green, A., Sicree, R., & King, H. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1047 · Cited by 15,297
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Standards of Medical Care in Diabetes
Power, D. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1593 · Cited by 8,673
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Cited by
Prediabetes: a high-risk state for diabetes development
Tabák, A. G., Herder, C., Rathmann, W., Brunner, E. J., & Kivimäki, M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60283-9 · Cited by 2,958
DeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., Hu, F. B., Kahn, C. R., Raz, I., Shulman, G. I., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.19 · Cited by 2,611
Self-citationMetformin—mode of action and clinical implications for diabetes and cancer
Pernicova, I., & Korbonits, M. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.256 · Cited by 1,349
Mitochondrial and metabolic dysfunction in ageing and age-related diseases
Amorim, J. A., Coppotelli, G., Rolo, A. P., Palmeira, C. M., Ross, J. M., & Sinclair, D. A. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00626-7 · Cited by 990
Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier
Divakaruni, A. S., Wiley, S. E., Rogers, G. W., Andreyev, A. Y., Petrosyan, S., Loviscach, M., Wall, E. A., Yadava, N., Heuck, A. P., Ferrick, D. A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303360110 · Cited by 308
“Thiazolidinediones (TZDs) are the most effective agents for preventing the progression from hyperglycemia to type 2 diabetes (6), and the increasingly appreciated link between dysregulated glucose metabolism and human disease has triggered the repurposing of pioglitazone to treat neurodegenerative conditions and certa…”
BackgroundDevelopment of type 2 diabetes mellitus in people with intermediate hyperglycaemia
Richter, B., Hemmingsen, B., Metzendorf, M.-I., & Takwoingi, Y. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012661.pub2 · Cited by 283
Assessment of Pancreatic β-Cell Function: Review of Methods and Clinical Applications
Cersosimo, E., Solis-Herrera, C., Trautmann, M., Malloy, J., & Triplitt, C. (2014) · Current Diabetes Reviews · doi:10.2174/1573399810666140214093600 · Cited by 281
“In the United States, some have predicted that approximately 40%-50% of individuals with prediabetes will progress to T2DM [39].”
BackgroundDynamics of diabetes and obesity: Epidemiological perspective
Boles, A., Kandimalla, R., & Reddy, P. H. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.01.016 · Cited by 263
Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes
Ferrannini, E., & DeFronzo, R. A. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv239 · Cited by 258
Self-citationObstructive Sleep Apnea and Type 2 Diabetes: Is There a Link?
Pamidi, S., & Tasali, E. (2012) · Frontiers in Neurology · doi:10.3389/fneur.2012.00126 · Cited by 231
“Subsequently, progressive decline in beta-cell function occurs, which leads to development of type 2 diabetes (DeFronzo and Abdul-Ghani, 2011).”
BackgroundPioglitazone: the forgotten, cost-effective cardioprotective drug for type 2 diabetes
DeFronzo, R. A., Inzucchi, S., Abdul-Ghani, M., & Nissen, S. E. (2019) · Diabetes and Vascular Disease Research · doi:10.1177/1479164118825376 · Cited by 223
Self-citationDepression and type 2 diabetes: A causal association?
Tabák, A. G., Akbaraly, T. N., Batty, G. D., & Kivimäki, M. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70139-6 · Cited by 167
Borden, P., Houtz, J., Leach, S. D., & Kuruvilla, R. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.06.019 · Cited by 192
Gallwitz, B., Guzman, J., Dotta, F., Guerci, B., Simó, R., Basson, B. R., Festa, A., Kiljański, J., Sapin, H., Trautmann, M., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60479-6 · Cited by 159
ADCY5 Couples Glucose to Insulin Secretion in Human Islets
Hodson, D. J., Mitchell, R. K., Marselli, L., Pullen, T. J., Gimeno Brias, S., Semplici, F., Everett, K. L., Cooper, D. M. F., Bugliani, M., Marchetti, P., et al. (2014) · Diabetes · doi:10.2337/db13-1607 · Cited by 147
“Although the maintenance of an adequate functional beta cell mass is critical to avoid the development of diabetes (3), the molecular basis of beta cell failure is still poorly understood (4).”
BackgroundSarkar, S., Das, D., Dutta, P., Kalita, J., Wann, S. B., & Manna, P. (2020) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2020.116594 · Cited by 159
Cefalu, W. T., Buse, J. B., Tuomilehto, J., Fleming, G. A., Ferrannini, E., Gerstein, H. C., Bennett, P. H., Ramachandran, A., Raz, I., Rosenstock, J., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0873 · Cited by 142
Obstructive Sleep Apnea in Young Lean Men
Pamidi, S., Wroblewski, K., Broussard, J., Day, A., Hanlon, E. C., Abraham, V., & Tasali, E. (2012) · Diabetes Care · doi:10.2337/dc12-0841 · Cited by 137
“However, our findings on glucose metabolism after ingestion of glucose load in the laboratory setting are entirely compatible with the well-documented natural history of type 2 diabetes, where the early stages involve normal glycemia associated with insulin resistance and compensatory hyperinsulinemia (38).”
Retnakaran, R., Kramer, C. K., Choi, H., Swaminathan, B., & Zinman, B. (2014) · Diabetes Care · doi:10.2337/dc14-0893 · Cited by 136
“Thus, the preservation of b-cell function remains an elusive goal in the management of T2DM (5,6).”
BackgroundBergman, M. (2012) · Endocrine · doi:10.1007/s12020-012-9830-9 · Cited by 165
Carlsson, L. M. S., Sjöholm, K., Karlsson, C., Jacobson, P., Andersson-Assarsson, J. C., Svensson, P.-A., Larsson, I., Hjorth, S., Neovius, M., Taube, M., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30061-x · Cited by 126
Beta-Cell Mass in Obesity and Type 2 Diabetes, and Its Relation to Pancreas Fat: A Mini-Review
Inaishi, J., & Saisho, Y. (2020) · Nutrients · doi:10.3390/nu12123846 · Cited by 107
Poolsup, N., Suksomboon, N., & Plordplong, N. (2016) · Diabetic Medicine · doi:10.1111/dme.12893 · Cited by 103
Varshney, R., Gupta, S., & Roy, P. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.02.033 · Cited by 107
The Pancreatic β-Cell: A Bioenergetic Perspective
Nicholls, D. G. (2016) · Physiological Reviews · doi:10.1152/physrev.00009.2016 · Cited by 98
Malin, S. K., Solomon, T. P. J., Blaszczak, A., Finnegan, S., Filion, J., & Kirwan, J. P. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00260.2013 · Cited by 98
“Thus, preservation of pancreatic -cell function in response to glucose is fundamental to preventing type 2 diabetes, particularly in obese individuals with impaired glucose tolerance that have lost 50–70% of their -cell function (7).”
BackgroundRole of AMPK in pancreatic beta cell function
Fu, A., Eberhard, C. E., & Screaton, R. A. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.06.020 · Cited by 114
“Furthermore, analysis of numerous clinical studies indicated that TZDs and metformin prevent the progression of diabetes in glucose intolerant individuals (reviewed in DeFronzo and Abdul-Ghani (2011)).”
Trimethylamine N-oxide impairs β-cell function and glucose tolerance
Kong, L., Zhao, Q., Jiang, X., Hu, J., Jiang, Q., Li, S., Peng, X., Wang, S., Chen, Y., Wan, Y., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46829-0 · Cited by 110
“Pioneering studieshaveshownthat β -cellfunctionisalready reduced to50to80% of normal at the time of T2D onset 4 .”
Hsueh, W., McLellan, K., Wyne, K., & Villagomez, E. (2014) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s39564 · Cited by 91
“41–43 While IFG is characterized by predominantly hepatic insulin resistance and normal muscle insulin sensitivity, IGT shows normal to slightly reduced hepatic insulin sensitivity and moderate to severe muscle insulin resistance.”
Varshney, R., Varshney, R., Mishra, R., Gupta, S., Sircar, D., & Roy, P. (2018) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2018.02.017 · Cited by 93
Curcumin and insulin resistance—Molecular targets and clinical evidences
Jiménez‐Osorio, A. S., Monroy, A., & Alavez, S. (2016) · BioFactors · doi:10.1002/biof.1302 · Cited by 93
“IR is one of the two main events that seem to be critical to the onset of T2DM, the second one being a progressive decline of b-cell function and insulin production [44].”
BackgroundNovel agents for the treatment of type 2 diabetes
DeFronzo, R. A., Triplitt, C. L., Abdul-Ghani, M., & Cersosimo, E. (2014) · Diabetes Spectrum · doi:10.2337/diaspect.27.2.100 · Cited by 83
Self-citationHe, Z., Hua, J., Qian, D., Gong, J., Lin, S., Xu, C., Wei, G., Meng, H., Yang, T., Zhou, B., et al. (2016) · Scientific Reports · doi:10.1038/srep38438 · Cited by 77
HIF-1α inhibitor PX-478 preserves pancreatic β cell function in diabetes
Ilegems, E., Bryzgalova, G., Correia, J. C., Yesildag, B., Berra, E., Ruas, J. L., Pereira, T., & Berggren, P. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.aba9112 · Cited by 78
Diagnosis and management of sensory polyneuropathy
Gwathmey, K. G., & Pearson, K. (2019) · BMJ · doi:10.1136/bmj.l1108 · Cited by 83
Importance of Beta Cell Function for the Treatment of Type 2 Diabetes
Saisho, Y. (2014) · Journal of Clinical Medicine · doi:10.3390/jcm3030923 · Cited by 82
Foghsgaard, S., Andreasen, C. H., Vedtofte, L., Andersen, E. S., Bahne, E., Strandberg, C., Buhl, T., Holst, J. J., Svare, J., Clausen, T. D., et al. (2016) · Diabetes Care · doi:10.2337/dc16-1017 · Cited by 77
Metformin for diabetes prevention: update of the evidence base
Gottwald‐Hostalek, U., & Campbell, I. W. (2021) · Current Medical Research and Opinion · doi:10.1080/03007995.2021.1955667 · Cited by 80
Sayers, S. R., Beavil, R. L., Fine, N. H. F., Huang, G. C., Choudhary, P., Pacholarz, K. J., Barran, P. E., Butterworth, S., Mills, C. E., Cruickshank, J. K., et al. (2019) · Diabetologia · doi:10.1007/s00125-019-05029-y · Cited by 66
Diet and prevention of type 2 diabetes mellitus: beyond weight loss and exercise
Palacios, O. M., Kramer, M. W., & Maki, K. C. (2018) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2019.1554430 · Cited by 73
“Fundamentally, the key to preventing T2DM is preservation of pancreatic beta-cell function [6], although various lines of evidence support the view that reducing IR can prevent or delay the progression of pancreatic beta-cell dysfunction [11].”
BackgroundStrategies for preventing type 2 diabetes: an update for clinicians
Khavandi, K., Amer, H., Ibrahim, B., & Brownrigg, J. (2013) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622313494986 · Cited by 62
Malin, S. K., Rynders, C. A., Weltman, J. Y., Barrett, E. J., & Weltman, A. (2016) · PLOS ONE · doi:10.1371/journal.pone.0154063 · Cited by 61
“Subsequently, maintaining the capacity of β-cells to secrete adequate amounts of insulin in response to multi-organ insulin resistance is paramount to preventing progression from prediabetes to type 2 diabetes [5].”
Malin, S. K., Bena, J., Abood, B., Pothier, C. E., Bhatt, D. L., Nissen, S. E., Brethauer, S. A., Schauer, P. R., Kirwan, J. P., & Kashyap, S. R. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12376 · Cited by 62
“Decompensated pancreatic β-cell insulin secretion for the prevailing degree of insulin resistance is the hallmark characteristic of type 2 diabetes disease severity [14, 15].”
BackgroundInterventions to Preserve Beta-Cell Function in the Management and Prevention of Type 2 Diabetes
Page, K. A., & Reisman, T. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0363-2 · Cited by 64
Guess, N. D. (2018) · Nutrients · doi:10.3390/nu10091245 · Cited by 75
“Preserving (or restoring) the first-phase insulin response should therefore be a focus of T2D prevention [69].”
BackgroundBehavioral approaches to nutrition and eating patterns for managing type 2 diabetes: A review
Salvia, M. G., & Quatromoni, P. A. (2023) · American Journal of Medicine Open · doi:10.1016/j.ajmo.2023.100034 · Cited by 90
Complications of Diabetes Therapy
Corathers, S. D., Peavie, S., & Salehi, M. (2013) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.06.005 · Cited by 65
Health risks and interventions in prediabetes: A review
Mahat, R. K., Singh, N., Arora, M., & Rathore, V. (2019) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2019.07.041 · Cited by 52
Biguanides drugs: Past success stories and promising future for drug discovery
Grytsai, O., Myrgorodska, I., Rocchi, S., Ronco, C., & Benhida, R. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113726 · Cited by 51
Compact NMR relaxometry of human blood and blood components
Cistola, D. P., & Robinson, M. D. (2016) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2016.04.020 · Cited by 51
Increased risk of dysglycaemia in South Africans with HIV; especially those on protease inhibitors
Levitt, N. S., Peer, N., Steyn, K., Lombard, C. J., Maartens, G., Lambert, E. V., & Dave, J. A. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.03.012 · Cited by 49
Rehman, K., Ali, M. B., & Akash, M. S. H. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.108670 · Cited by 57
Continuous glucose monitoring system and new era of early diagnosis of diabetes in high risk groups
Soliman, A. T., Desanctis, V., Yassin, M. A., Elalaily, R., & Eldarsy, N. (2014) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.131130 · Cited by 51
“[20,21] De Fronzo et al., studied 602 subjects with IGT, 115 with normal glucose tolerance (NGT) and 50 with IFG.”
β-Cell Dysfunction Is Associated with Metabolic Syndrome Severity in Adults
Malin, S. K., Finnegan, S., Fealy, C. E., Filion, J., Rocco, M. B., & Kirwan, J. P. (2013) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2013.0083 · Cited by 48
Kieswich, J., Sayers, S. R., Silvestre, M. F., Harwood, S. M., Yaqoob, M. M., & Caton, P. W. (2016) · Diabetologia · doi:10.1007/s00125-016-4076-3 · Cited by 47
“Type 2 diabetes is characterised by the presence of peripheral insulin resistance and pancreatic beta cell dysfunction [1].”
BackgroundSong, W.-J., Mondal, P., Li, Y., Lee, S. E., & Hussain, M. A. (2013) · Diabetes · doi:10.2337/db12-1394 · Cited by 46
“Failure of b-cells to adequately respond to increased metabolic demand on insulin secretion (b-cell dysfunction) results in diabetes (1,2).”
BackgroundFerreira, M. A., Gomes, A. P. O., de Moraes, A. P. G., Stringhini, M. L. F., Mota, J. F., Coelho, A. S. G., & Botelho, P. B. (2017) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2017.08.008 · Cited by 48
An Insulin-Sensitizing Thiazolidinedione, Which Minimally Activates PPARγ, Does Not Cause Bone Loss
Fukunaga, T., Zou, W., Rohatgi, N., Colca, J. R., & Teitelbaum, S. L. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2364 · Cited by 45
Ochman, A. R., Lipinski, C. A., Handler, J. A., Reaume, A. G., & Saporito, M. S. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.192187 · Cited by 47
Smith, D. L., Orlandella, R. M., Allison, D. B., & Norian, L. A. (2020) · GeroScience · doi:10.1007/s11357-020-00278-x · Cited by 48
Bardini, G., Dicembrini, I., Rotella, C. M., & Giannini, S. (2011) · Acta Diabetologica · doi:10.1007/s00592-011-0339-0 · Cited by 43
“Subjects underwent to an OGTT showed that the conversion from NGT to IGT is characterized by an increase in insulin resistance and a progressive decrease in insulin secretion with reduced insulinogenic index [1, 13, 14].”
Does Disruption of Circadian Rhythms Contribute to Beta-Cell Failure in Type 2 Diabetes?
Rakshit, K., Thomas, A. P., & Matveyenko, A. V. (2014) · Current Diabetes Reports · doi:10.1007/s11892-014-0474-4 · Cited by 48
“A recent study also demonstrated glucose intolerance and decline in disposition index following 1 week of sleep restriction, although this Curr Diab Rep (2014) 14:474 Page 3 of 8, 474”
InfluentialRedox Homeostasis in Pancreatic Cells
Ježek, P., Dlasková, A., & Plecitá‐Hlavatá, L. (2012) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2012/932838 · Cited by 45
“Excellent recent reviews cover gathered knowledge of all aspects of pancreatic β cell biology, development, molecular physiology, and medical aspects [1–19].”
BackgroundCircadian variation of the pancreatic islet transcriptome
Rakshit, K., Qian, J., Ernst, J., & Matveyenko, A. V. (2016) · Physiological Genomics · doi:10.1152/physiolgenomics.00019.2016 · Cited by 42
“Understanding of mechanisms underlying failed islet function and survival in T2DM is essential for development of novel therapeutic and preventative approaches (10).”
BackgroundKalamkar, S., Acharya, J., Madathil, A. K., Gajjar, V., Divate, U., Karandikar-Iyer, S., Goel, P., & Ghaskadbi, S. (2022) · Antioxidants · doi:10.3390/antiox11051026 · Cited by 30
Lee, H., Wei, D., & Loeken, M. R. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2451 · Cited by 39
Ouwens, D. M., Bekaert, M., Lapauw, B., Nieuwenhove, Y. V., Lehr, S., Hartwig, S., Calders, P., Kaufman, J., Sell, H., Eckel, J., et al. (2012) · Archives of Physiology and Biochemistry · doi:10.3109/13813455.2012.654800 · Cited by 38
“Insulin resistance, i.e. a reduced effectiveness of insulin in lowering blood sugar levels, predicts and precedes metabolic disorders like type 2 diabetes mellitus and cardiovascular disease (Defronzo & Abdul-Ghani, 2011; Knowler et al., 2002).”
BackgroundValencia, W. M., Stoutenberg, M., & Florez, H. (2014) · Current Diabetes Reports · doi:10.1007/s11892-014-0539-4 · Cited by 37
Association between beta cell function and future glycemic control in patients with type 2 diabetes
Saisho, Y., Kou, K., Tanaka, K., Abe, T., Shimada, A., Kawai, T., & Itoh, H. (2013) · Endocrine Journal · doi:10.1507/endocrj.ej12-0416 · Cited by 36
Gao, L.-H., Liu, Q., Liu, S., Chen, Z., Li, C.-N., Lei, L., Sun, S., Li, L., Liu, J., & Shen, Z. (2013) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2013.11.024 · Cited by 41
Hou, X., Liu, J., Song, J., Wang, C., Liang, K., Sun, Y. S., Ma, Z., Yang, W., Li, C., Zhang, X., et al. (2015) · Journal of Diabetes Research · doi:10.1155/2016/8797316 · Cited by 35
“Individuals with an A1c of 7-8% were more likely to be older and stronger and have a higher diastolic BP than those with an A1c 6.5%.”
BackgroundInfluentialBagepally, B. S., Chaikledkaew, U., Gurav, Y. K., Anothaisintawee, T., Youngkong, S., Chaiyakunapruk, N., McEvoy, M., Attia, J. R., & Thakkinstian, A. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-001020 · Cited by 36
Multi-omics approaches for biomarker discovery and precision diagnosis of prediabetes
Song, J., Wang, C., Zhao, T., Zhang, Y., Xing, J., Zhao, X., Zhang, Y., & Zhang, Z. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1520436 · Cited by 52
Detecting people at high risk of type 2 diabetes- How do we find them and who should be treated?
Kong, A. P. S., Luk, A. O. Y., & Chan, J. C. N. (2016) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2016.06.003 · Cited by 39
Ethnic Similarities and Differences in the Relationship between Beta Cell Mass and Diabetes
Inaishi, J., & Saisho, Y. (2017) · Journal of Clinical Medicine · doi:10.3390/jcm6120113 · Cited by 38
“This point emphasizes that it is important to preserve or recover functional beta cell mass as a management and treatment strategy for T2DM [38].”
BackgroundWang, Y., Wang, A., Alkhalidy, H., Luo, J., Moomaw, E., Neilson, A. P., & Liu, D. (2020) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201900978 · Cited by 41
Chronic Microvascular Complications in Prediabetic States—An Overview
Baranowska-Jurkun, A., Matuszewski, W., & Bandurska-Stankiewicz, E. M. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9103289 · Cited by 43
“FPG is correct with small changes of insulin sensitivity in the liver, and early and late phase of insulin secretion is impaired [21,22,31], while the main place of insulin resistance occurs in the muscles [20,22].”
BackgroundMethodThe islet circadian clock: entrainment mechanisms, function and role in glucose homeostasis
Rakshit, K. P., Qian, J., Colwell, C. S., & Matveyenko, A. V. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12523 · Cited by 37
Palacios, O. M., Maki, K. C., Xiao, D., Wilcox, M. L., Dicklin, M. R., Kramer, M. W., Trivedi, R., Burton‐Freeman, B. M., & Edirisinghe, I. (2019) · Journal of the American College of Nutrition · doi:10.1080/07315724.2019.1660929 · Cited by 34
“Tree nut consumption, including almonds, has been associated with lower risk of both T2D and CVD and with favorable changes in the metabolic profile, including improved lipoprotein lipid levels and reduced concentrations of fasting insulin and glucose (15–20).”
BackgroundInfluentialVarvel, S. A., Pottala, J. V., Thiselton, D. L., Caffrey, R., Dall, T., Sasinowski, M., McConnell, J. P., Warnick, G. R., Vörös, S., & Graham, T. E. (2014) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2014-000038 · Cited by 35
Targeting the intestinal L-cell for obesity and type 2 diabetes treatment
Albrechtsen, N. J. W., Kuhre, R. E., Deacon, C. F., & Holst, J. J. (2013) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2014.862152 · Cited by 34
Circadian Genes as Therapeutic Targets in Pancreatic Cancer
García-Costela, M., Escudero-Feliú, J., Puentes-Pardo, J. D., Moreno-SanJuan, S., Morales, S., Ríos‐Arrabal, S., Carazo, Á., & León, J. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00638 · Cited by 33
“TEF seems to control the expression of GLUT2 under circadian behavior (119), meanwhile DBP regulates the circadian expression of ARNT/HIF-1β , which may have a role in connecting circadian rhythm and metabolism, being impaired in T2DM (120).”
BackgroundInfluentialMalin, S. K., Kashyap, S., Hammel, J. P., Miyazaki, Y., DeFronzo, R. A., & Kirwan, J. P. (2014) · Diabetes Care · doi:10.2337/dc13-3011 · Cited by 31
“In conclusion, GSIS is essential for preventing the progression from normal glucose tolerance to type 2 diabetes (1,2,30).”
BackgroundSelf-citationCinti, F., Mezza, T., Severi, I., Suleiman, M., CEFALO, C. M. A., Sorice, G. P., Moffa, S., Impronta, F., Quero, G., Alfieri, S., et al. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154414 · Cited by 31
Malin, S. K., Kirwan, J. P., Sia, C. L., & González, F. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3177 · Cited by 30
Heianza, Y., Arase, Y., Fujihara, K., Tsuji, H., Saito, K., Hsieh, S. D., Kodama, S., Shimano, H., Yamada, N., Hara, S., et al. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03667.x · Cited by 30
Xiu, L., Lin, M., Liu, W., Kong, D., Liu, Z., Zhang, Y., Ouyang, P., Liang, Y., Zhong, S., Chen, C., et al. (2015) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2014.0344 · Cited by 28
Lu, Y., Xu, J., Li, Y., Wang, R., Dai, C., Zhang, B., Zhang, X., Xu, L., Tao, Y., Han, M., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.ade8647 · Cited by 32
“Under pathological conditions, the apoptosis of β cells caused by multiple factors underlies the development of T2D ( 51 – 53 ).”
BackgroundChanging the Concept of Type 2 Diabetes: Beta Cell Workload Hypothesis Revisited
Saisho, Y. (2018) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530318666180821161825 · Cited by 30
Rajabi‐Naeeni, M., Dolatian, M., Qorbani, M., & Vaezi, A. A. (2020) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-020-00549-9 · Cited by 29
Saisho, Y. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1776262 · Cited by 28
Pancreatic Islet Responses to Metabolic Trauma
Burke, S. J., Karlstad, M. D., & Collier, J. J. (2016) · Shock · doi:10.1097/shk.0000000000000607 · Cited by 30
Viskochil, R. H., Malin, S. K., Blankenship, J. M., & Braun, B. (2017) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00790.2016 · Cited by 31
“Up to 70% of individuals with prediabetes (fasting and/or postchallenge glucose concentrations above normal but below the range of frank T2D) are characterized by an inappropriate matching of insulin secretion and sensitivity (7), and without lifestyle or pharmacological intervention the transition from prediabetes to…”
BackgroundMalin, S. K., Navaneethan, S. D., Mulya, A., Huang, H., & Kirwan, J. P. (2014) · The journal of nutrition health & aging · doi:10.1007/s12603-014-0459-7 · Cited by 27
“this reduction in compensatory hyperinsulinemia to glucose loads in insulin resistant adults is considered beneficial for preserving pancreatic beta-cell function and improving long-term glycemic control (48).”
Thota, R. N., Acharya, S., Abbott, K. A., & Garg, M. L. (2016) · Trials · doi:10.1186/s13063-016-1702-9 · Cited by 31
“The presence of insulin resistance in prediabetes also modulates the risk of developing T2D, and individuals with combined IGT and IFG are at greater risk of developing T2D than those with IFG or IGT alone [6, 15].”
BackgroundMalin, S. K., François, M. E., Eichner, N. Z. M., Gilbertson, N. M., Heiston, E. M., Fabris, C., & Breton, M. D. (2018) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00680.2018 · Cited by 27
“Journal of Applied Physiology, 125 (6), 1979-1986.”
BackgroundElevated NEFA levels impair glucose effectiveness by increasing net hepatic glycogenolysis
Kehlenbrink, S., Koppaka, S., Martin, M., Relwani, R., Cui, M.-H., Hwang, J., Li, Y., Basu, R., Hawkins, M., & Kishore, P. (2012) · Diabetologia · doi:10.1007/s00125-012-2662-6 · Cited by 23
“insulin concentrations in the presence of hyperglycaemia, as in the present study) is expected to occur rather late in the progressive course of the disease due to advanced beta cell failure [35].”
ResultPark, S., Kang, S., Kim, D. S., Shin, B.-K., Moon, N. R., & Daily, J. W. (2014) · Free Radical Research · doi:10.3109/10715762.2014.917410 · Cited by 25
Malin, S. K., Hinnerichs, K. R., Echtenkamp, B. G., Evetovich, T. K., & Engebretsen, B. J. (2013) · European Journal of Applied Physiology · doi:10.1007/s00421-013-2725-5 · Cited by 27
Robinson, M. D., Mishra, I., Deodhar, S., Patel, V., Gordon, K. V., Vintimilla, R., Brown, K., Johnson, L. A., O’Bryant, S. E., & Cistola, D. P. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1359-5 · Cited by 23
“Since the primary goal of type 2 diabetes prevention is preserving β-cell function [25], the glucose criterion of MetS is inadequate for the early detection of diabetes risk.”
Background
Metadata
- Authors
- DeFronzo, R. A., & Abdul-Ghani, M. A.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- ORCID
- DeFronzo, Ralph A.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2011-08
- Volume
- 96
- Issue
- 8
- Pages
- 2354-2366
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2131616886
- Cited by
- 247
- References
- 131
- Citations by year
- 2026: 8 · 2025: 13 · 2024: 15 · 2023: 13 · 2022: 7 · 2021: 11 · 2020: 23 · 2019: 12 · 2018: 18 · 2017: 16 · 2016: 19 · 2015: 14 · 2014: 31 · 2013: 28 · 2012: 17
- FWCI
- 20.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- type 2 diabetes prevention, impaired glucose tolerance, beta-cell preservation, insulin resistance, thiazolidinediones, metformin, glucagon-like peptide-1 analogues, acarbose, lifestyle modification, pharmacological interventions, prediabetes
- MeSH terms
- Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Prediabetic State, Insulin-Secreting Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.